Insulin glargine 1 is under clinical development by Gan & Lee Pharmaceuticals and currently in Phase I for Type 2 Diabetes. According to GlobalData, Phase I drugs for Type 2 Diabetes have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Insulin glargine 1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Insulin glargine 1 overview
Insulin glargine is under development for the treatment of type 1 diabetes and type 2 diabetes. It is administered through subcutaneous route. The drug candidate acts by targeting insulin receptor (IR).
Gan & Lee Pharmaceuticals overview
Gan & Lee Pharmaceuticals (Gan & Lee), formerly Beijing Gan & Lee Biotechnology, is a biopharmaceutical company. It carries out the research and development, production and sales of recombinant insulin analog APIs and injections. The company product portfolio includes long-acting insulin glargine injection, fast-acting insulin lispro injection, insulin aspart injection, lispro mixed injection, premixed protamine human insulin mixed injection. Gan & Lee also offers cover related medical devices, including reusable insulin injection pens and disposable pen needle. The company utilizes its patented intramolecular chaperone technology for production of recombinant human insulin and insulin analogs. Gan & Lee is headquartered in Beijing, China.
For a complete picture of Insulin glargine 1’s drug-specific PTSR and LoA scores, buy the report here.